7152-19-4

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
2-CYANOAMINO-4-HYDROXY-6-METHYLPYRIMIDINE is used as a key intermediate in the synthesis of various drugs and organic compounds, contributing to the development of new medicinal agents.
Used in Synthesis of Organic Compounds:
2-CYANOAMINO-4-HYDROXY-6-METHYLPYRIMIDINE serves as a building block in the creation of diverse organic compounds, expanding the scope of chemical research and applications.
Used in Antifungal and Antibacterial Applications:
2-CYANOAMINO-4-HYDROXY-6-METHYLPYRIMIDINE has been studied for its potential biological activities, including its use as an antifungal and antibacterial agent, indicating its potential in combating infections and promoting health.

InChI:InChI=1/C6H6N4O/c1-4-2-5(11)10-6(9-4)8-3-7/h2H,1H3,(H2,8,9,10,11)

Upstream product

• 141-52-6 sodium ethanolate 
• 141-97-9 ethyl acetoacetate 
• 127099-85-8 N-Cyanoguanidine 

Downstream Products

• 284665-60-7 N-(2-fluoro-phenyl)-N'-(4-hydroxy-6-methyl-pyrimidin-2-yl)-guanidine 
• 71523-76-7 N-(4-hydroxy-6-methyl-pyrimidin-2-yl)-N'-(4-trifluoromethyl-phenyl)-guanidine 
• 131699-74-6 N-(4-hydroxy-6-methyl-pyrimidin-2-yl)-N'-(3-nitro-phenyl)-guanidine 
• 16018-52-3 N-(4-methyl-6-oxo-1,6-dihydro-pyrimidin-2-yl)-N'-phenyl-guanidine 
• 36108-05-1 N-(4-methyl-6-oxo-1,6-dihydro-pyrimidin-2-yl)-N'-(3-trifluoromethyl-phenyl)-guanidine 
• 326012-75-3 N-(4-hydroxy-6-methyl-pyrimidin-2-yl)-N'-(2-methoxy-phenyl)-guanidine 
• 510738-19-9 N-(4-hydroxy-6-methyl-pyrimidin-2-yl)-N'-(3-methoxy-phenyl)-guanidine 
• 873943-92-1 N-(2,6-difluoro-phenyl)-N'-(4-hydroxy-6-methyl-pyrimidin-2-yl)-guanidine 
• 510738-25-7 N-(2,4-difluoro-phenyl)-N'-(4-hydroxy-6-methyl-pyrimidin-2-yl)-guanidine 

Relevant academic research and scientific papers

Regioselective synthesis of pyrimido[1,2-a][1,3,5]triazin-6-ones via reaction of 1-(6-oxo-1,6-dihydropyrimidin-2-yl)guanidines with triethylorthoacetate: Observation of an unexpected rearrangement

A novel thermal rearrangement, involving pyrimidine ring opening and subsequent ring closure leading to recyclization of the system, was identified in the reaction of (6-oxo-1,6-dihydropyrimidin-2-yl)guanidines 3 (where NR 1R2 = NH2, NH alkyl, NH aralkyl, NHCH 2Ph(R)) with triethyl orthoacetate, affording 4-substituted-2-methyl- 6H-pyrimido[1,2-a][1,3,5]triazin-6-ones 6 and their ring opened products. However, no such rearrangement was observed with (6-oxo-1,6-dihydropyrimidin-2- yl)guanidines 3 bearing a tertiary amino or anilino substituent (i.e. where NR1R2 = N(CH3)2, indoline, morpholino, NHAr). As expected, 2-substituted-4-methyl-6H-pyrimido[1,2-a][1,3,5] triazin-6-ones 4 were obtained as the final products. Experimental structural determination and theoretical studies were carried out to get an understanding of the observed thermal rearrangement. In addition, an attempt to obtain similar pyrimido[1,2-a][1,3,5]triazin-6-ones using N,N-dimethylacetamide dimethyl acetal (DMA-DMA) as one carbon inserting synthon had furnished triazine ring annulated product 14 bearing N,N-dimethyl enamino substituent at position 4 as a result of further reaction with a second molecule of DMA-DMA.

Synthesis and structure activity relationship of guanidines as NPY Y5 antagonists

A series of bis-aryl substituted guanidines have been discovered as potent NPY Y5 antagonists. The SAR and in vitro metabolic stability of these compounds are discussed.